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Abstract
Background: Pulmonary Arterial Hypertension (PAH) remains a therapeutic challenge, and the search continues for
more effective drugs and drug combinations. We recently reported that deletion of the vasoactive intestinal
peptide (VIP) gene caused the spontaneous expression of a PH phenotype that was fully corrected by VIP. The
objectives of this investigation were to answer the questions: 1) Can VIP protect against PH in other experimental
models? and 2) Does combining VIP with an endothelin (ET) receptor antagonist bosentan enhance its efficacy?
Methods: Within 3 weeks of a single injection of monocrotaline (MCT, s.c.) in Sprague Dawley rats, PAH developed,
manifested by pulmonary vascular remodeling, lung inflammation, RV hypertrophy, and death within the next 2
weeks. MCT-injected animals were either untreated, treated with bosentan (p.o.) alone, with VIP (i.p.) alone, or with
both together. We selected this particular combination upon finding that VIP down-regulates endothelin receptor
expression which is further suppressed by bosentan. Therapeutic outcomes were compared as to hemodynamics,
pulmonary vascular pathology, and survival.
Results: Treatment with VIP, every other day for 3 weeks, begun on the same day as MCT, almost totally
prevented PAH pathology, and eliminated mortality for 45 days. Begun 3 weeks after MCT, however, VIP only
partially reversed PAH pathology, though more effectively than bosentan. Combined therapy with both drugs fully
reversed the pathology, while preventing mortality for at least 45 days.
Conclusions: 1) VIP completely prevented and significantly reversed MCT-induced PAH; 2) VIP was more effective
than bosentan, probably because it targets a wider range of pro-remodeling pathways; and 3) combination
therapy with VIP plus bosentan was more effective than either drug alone, probably because both drugs
synergistically suppressed ET-ET receptor pathway.
Keywords: Pulmonary Hypertension, Vasoactive Intestinal Peptide, Endothelin Receptor Antagonist, Pulmonary Vas-
cular Remodeling, Monocrotaline
Background
The pathogenesis of pulmonary arterial hypertension
(PAH) is incompletely understood, and its treatment
remains imperfect. The principal pathologic lesions of
pulmonary vascular remodeling, inflammation, and right
ventricular hypertrophy (RVH), involve genetic and
environmental factors, and are mediated by imbalances
in key pathways that either promote or modulate their
development [1-3].
Research into the causation and treatment of PAH is
heavily dependent on experimental models that mimic
the disease. Among these is the uniformly fatal model of
PAH induced in rats by monocrotaline (MCT), the
toxin derived from Crotolaria spectabilis [4]. Despite its
imperfections [5,6], this model has long been used to
clarify the pathogenesis of PAH, and test the therapeutic
potential of new drugs for its management. In the conti-
nuing search for more effective therapies, a recent
review discussed some of these drugs: Tyrosine kinase
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inhibitors (platelet-derived growth factor and epidermal
growth factor receptor inhibitors), multikinase inhibitors
(tyrosine kinase and serine/threonine kinase), elastase
inhibitors, Rho kinase inhibitors, endothelial nitric oxide
synthase-related agents, survivin inhibitors, HMG-COA
reductase inhibitors, and peptides, including vasoactive
intestinal peptide (VIP) and adrenomedullin [7].
VIP relaxes pulmonary vascular smooth muscle [8,9],
neutralizes a variety of pulmonary vasoconstrictors,
including endothelin [10] and hypoxia [11], inhibits air-
way and pulmonary vascular smooth muscle cell prolif-
eration [12,13], and has broad anti-inflammatory actions
[14]. We recently reported that mice with targeted dele-
tion of the VIP gene express a spontaneous phenotype
of PAH, without the added stimulus of hypoxia [15].
Treatment of the VIP-deficient mice with VIP corrected
the key features of the disease: vascular remodeling,
RVH, and lung inflammation [15-17]. VIP has also
already been the subject of 2 clinical trials in human
PAH, with conflicting results [13,18].
The primary objectives of the present study were to
answer 2 questions: a) Is VIP effective in preventing and
reversing a model of PAH, such as that induced by
MCT, which is both widely used and not directly attri-
butable to VIP deficiency? b) Can the effectiveness of
VIP against experimental PAH be enhanced by combin-
ing it with another anti-proliferative agent such as
bosentan, itself with proven benefit in the MCT model
[19]; as well as in clinical PAH [2]? The selection of
bosentan seemed particularly appropriate because we
had earlier reported that VIP modulated hypoxic pul-
monary hypertension in Fawn-hooded rats, by suppres-
sing the expression of both endothelin (ET) and its
receptors [11]. Thus, we reasoned that the combination
of VIP and bosentan might exert a more powerful effect
against the endothelin system, and possibly against
other pathways that mediate vascular remodeling [20].
The results validate this expectation.
Methods
Ethics Statement
All experiments and animal care procedures were
approved by the Institutional Animal Care and Use
Committee (IACUC) at SUNY Stony Brook (Permit
number: 20101678) and at Northport VA Medical Cen-
ter (Permit number: 00328), and were carried out in
strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health.
Animals
Sprague Dawley rats, 200-230 g, 6-8-week old, were
from Taconic Labs (Germantown, NY). All surgical pro-
cedures were performed under anesthesia, and every
effort was made to minimize suffering.
Chemicals and reagents
MCT was from Sigma-Aldrich (St. Louis, MO); VIP was
from Bachem Americas Inc. (Torrance, CA); and bosen-
tan was provided by Actelion Pharmaceutical Ltd.
(Allschwil, Switzerland).
Study Design
The study was designed to test 3 objectives:
1) Prevention by VIP
2 groups of rats were injected with MCT (a single s.c.
injection of 60 mg/kg). Group 1 (n = 10) rats received
no additional treatment; group 2 (n = 10) rats received
VIP at 500 μg/kg, i.p. (in 0.2 ml PBS), every other day
for 3 weeks, beginning the same day as MCT, for a total
of 10 injections. This is the same VIP dose regimen we
used to reverse the PAH phenotype caused by deletion
of the VIP gene (15). A third group of 10 rats, serving
as controls, received neither MCT nor VIP. Survival was
monitored for 45 days in a fourth group of 8 rats that
received a single dose of MCT plus VIP, as above.
2) Reversal by VIP or bosentan
A group of 10 rats received VIP at 500 μg/kg, i.p. (in 0.2
ml PBS), every other day for 3 weeks, beginning 3 weeks
after the injection of MCT, i.e., after PAH pathology
had already developed. Another group of 10 rats
received bosentan at 300 mg/kg/day, as food admix
(Product # TD.09065, Harlan Laboratories Inc., WI), for
3 weeks, beginning 3 weeks after MCT.
3) Reversal by combination therapy
Three weeks after MCT injection, another group of rats
(n = 10) received both VIP and bosentan, as above, also
for 3 weeks.
Measurements
All rats were subjected to the following measurements, 3
weeks following the single injection of MCT in the pre-
vention studies, and 3 weeks after the pathology had
already developed (6 weeks after MCT) in the reversal
experiments.
Hemodynamic measurements
Rats were anesthetized with i.p. ketamine (100 mg/kg)
and Fentanyl (0.05 mg/kg). A 1.4 F Mikro-Tip pressure
transducer catheter (Millar Instruments Inc., Houston,
TX) was inserted through the right jugular vein and
advanced to the right ventricle for digital recording of
RV (or PA) systolic pressure.
Histological examination & morphometric analysis
The animals were euthanized by an injection of 120 mg/
kg of pentobarbital, the chest was opened, and the right
main-stem bronchus was tied off. For all histological
procedures, the upper and middle lobes of the right
lung were fully inflated and fixed by intra-tracheal instil-
lation of 2 ml 10% buffered formalin, then embedded in
paraffin. Sections (4 μm thick) were stained with
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hematoxylin and eosin or Masson’s Trichrome for gen-
eral morphologic and morphometric analysis. Measure-
ments were made of 4 separate pulmonary arterioles
from each lung, and averaged to 1 set of values. Only
arteries near smaller bronchi or terminal bronchioles, 50-
80 μm in diameter, were selected for analysis. The Image
J program, version 1.34r (http://rsb.info.nih.gov/ij/), was
used for measurement of total vessel area (μm2), luminal
area (μm2), and inner circumference (μm). Medial area
(μm2) was calculated as the difference between total and
luminal areas. Standard medial thickness (μm) was calcu-
lated as the ratio of medial area to inner circumference,
as described [15,21].
Anatomic assessment of RV hypertrophy
The heart was isolated and placed under a dissecting
microscope. Attached vessels and both atria were dis-
sected and removed. The RV wall was cut out, blotted,
and weighed, then the left ventricular wall and septum
(LV+septum) were treated in the same way. The RV/
(LV+Septum) weight ratio was calculated as an index of
RV hypertrophy.
Assessment of lung inflammation
Lung sections were examined by a pathologist who was
blinded to the identities of the samples. Inflammation
was graded 0, 1, 2, 3, or 4, based on the intensity and
extent of perivascular and peribronchiolar inflammatory
cell infiltrates.
Survival
After a single injection of MCT, all rats were monitored
for 45 days. Mortality data were compared among all
experimental groups, by the log-rank test, and Kaplan-
Meier plots.
Statistical analysis
Quantitative data from all groups were analyzed by
ANOVA and Tukeys post-hoc test for multiple compari-
sons. A P value of < 0.05 was considered significant.
Results and discussion
Results
MCT-induced PAH (Table 1, Figures 1 &2)
As reported by others [22], a single injection of MCT
resulted in full development of pulmonary vascular
pathology within 3 weeks. RV systolic pressure was
significantly elevated relative to levels in control,
untreated rats. Small pulmonary arteries and arterioles
had thickened media (20.4 ± 1.1 μM vs. 8.5 ± 0.5 μM,
P< 0.001, n = 10), and narrower lumen than control ves-
sels of similar diameter (50-80 μm). The corresponding
ratio of medial area to luminal area in MCT-treated rats
was significantly elevated, as was the RV/(LV+septum)
weight ratio. The lungs showed perivascular and peri-
bronchiolar inflammatory cell infiltrates, predominantly
macrophages and lymphocytes. All MCT-treated rats
died within 3-5 weeks after MCT injection, with no
mortality noted in the control group.
Prevention of PAH by VIP (Table 1, Figures 1 &2)
In MCT-injected rats that were co-treated with VIP, all
hemodynamic, histologic, morphometric, and pathologic
findings were statistically unchanged from the control,
Table 1 The PAH Phenotype in MCT-Injected Rats: Near-Full Prevention by Early Treatment with VIP *
Measurements Control, untreated MCT + P value (post hoc)
0 VIP † ** ††
RV systolic pressure (mm Hg) 24.3 ± 2.4 61.4 ± 4.8 29.9 ± 1.8 < 0.05 < 0.05 NS
Arteriolar medial/luminal area 0.76 ± 0.07 3.9 ± 0.51 1.5 ± 0.2 < 0.05 < 0.05 NS
RV/(LV+septum) weight ratio 0.26 ± 0.01 0.56 ± 0.03 0.35 ± 0.01 < 0.05 < 0.05 NS
Lung inflammation (0-4) 0.20 ± 0.17 3.0 ± 0.26 0.3 ± 0.21 < 0.05 < 0.05 NS
* VIP treatment was begun on the same day as MCT. ANOVA: p < 0.0001
† MCT alone vs. control; ** VIP pretreatment vs. MCT alone; †† VIP pretreatment vs. control.
Figure 1 Rat lung sections (H&E) showing MCT-induced
vascular thickening and its attenuation by VIP, bosentan, or
their combination. Small pulmonary arteries from MCT-treated rats
had thickened media and narrowed lumen compared to arteries of
similar diameter (70-80 μm) from control, untreated rats (A, B, P<
0.001). Treatment with either VIP or bosentan (C, D) resulted in
significant attenuation of these changes: the ratio of medial area to
luminal area in VIP-treated rats was significantly reduced (P< 0.05).
In rats receiving a combination of VIP and bosentan (E), the medial
area/luminal area ratio was almost the same as in control untreated
rats (magnification: X20).
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untreated group. As well, all animals in this group were
alive 45 days after the MCT injection.
Reversal of PAH by VIP (Table 2, Figures 1 &2)
When VIP treatment was begun 3 weeks after MCT
injection, RV systolic pressure was considerably lower
than in MCT-treated rats (33 ± 0.5 vs. 61.4 ± 4.8 mm
Hg, n = 5, P< 0.05), but still higher than in control,
untreated rats (24.3 ± 2.4 mm Hg). The ratio of medial
area to luminal area in this group was also well below
that in MCT-treated rats (1.68 ± 0.19 vs. 3.9 ± 0.51, n =
7, P< 0.05), but higher than in control, untreated rats
(0.76 ± 0.07, P< 0.05). The most prominent improve-
ment was in the intensity/extent of inflammatory cell
infiltrates, which was down to the minimal value of 0.3
± 0.21, no different from the control untreated group
(0.2 ± 0.17). However, the RV/(LV+septum) weight ratio
was only slightly but not significantly reduced (0.51 ±
0.03 vs.0.56 ± 0.03, n = 10, P:NS). Treatment with VIP
also markedly reduced mortality (to 29%, P< 0.0001).
Reversal of PAH by bosentan (Table 2, Figures 1 &2)
Like VIP, bosentan significantly reduced RV systolic
pressure, though somewhat less effectively (to 39 ± 1.2
mm Hg). Pulmonary vascular thickening was similarly
reduced (medial area/luminal area: to 1.76 ± 0.19), but
RV/(LV+septum) weight ratio was only slightly but not
significantly reduced, and bosentan was less effective
than VIP in attenuating the intensity and extent of
inflammatory cell infiltrates (to 1.2 ± 0.3). As with VIP,
overall mortality was reduced to 29%, P< 0.0001.
Reversal of PAH by combination of bosentan and VIP
(Table 2, Figures 1 &2)
MCT-injected rats co-treated with VIP and bosentan
had RV systolic pressure almost as low as in control,
untreated rats (26.0 ± 1.2 vs. 24.3 ± 2.4 mm Hg, n = 5,
P = NS), had normal or near-normal medial area/lumi-
nal area ratio (n = 8, P = NS), and almost no inflamma-
tory cell infiltrates. RV/LV+septum ratio was reduced to
levels statistically no different from those in control
untreated group (0.26 ± 0.01). Finally, no mortality was
observed over the 45-day observation period.
Discussion
Our findings with the induction of PAH following a sin-
gle injection of monocrotaline in rats are in agreement
with reports by other investigators who have studied
this experimental model [22]. The pathologic and patho-
physiologic features included 4 key elements: a) RV sys-
tolic hypertension; b) right ventricular hypertrophy c)
perivascular inflammatory cells infiltrates; and d) remo-
deling of smaller pulmonary arteries, mainly by smooth
muscle cell and collagen proliferation. The additional
lesion of neointimal proliferation, seen in severe human
disease, has been reported in rats receiving MCT follow-
ing pneumonectomy, or in conjunction with other pro-
cedures [5,6].
The complex pathogenesis of MCT- induced PAH
Strong evidence supports the view that monocrotaline
induces pulmonary vascular pathology via multiple
Figure 2 Kaplan-Meier plot of survival over 45 days. Rats were
observed for 45 days after MCT injection. MCT was uniformly fatal
within 35 days. Early (preventive) treatment with VIP was followed
by no mortality for 45 days, i.e., just as in control, untreated rats.
Treatment with either bosentan or VIP alone, begun at 21 days,
reduced mortality in MCT-treated rats by 29% (P< 0.0001). No
mortality was observed during the same time period in rats that
received both bosentan and VIP.
Table 2 Reversal of MCT-Induced PAH by VIP, Bosentan, or Their Combination
Measurements Control, untreated MCT + P value (post hoc)
0 VIP Bosentan VIP + Bosentan * † **
RV systolic pressure (mm Hg) 24.3 ± 2.4 61.4 ± 4.8 33 ± 0.5 39 ± 1.2 26.0 ± 1.2 < 0.05 < 0.05 < 0.05
Arteriolar medial/luminal area 0.76 ± 0.07 3.9 ± 0.51 1.68 ± 0.19 1.76 ± 0.19 0.79 ± 0.05 < 0.05 < 0.05 < 0.05
RV/(LV+septum) weight ratio 0.26 ± 0.01 0.56 ± 0.03 0.51 ± 0.03 0.47 ± 0.07 0.34 ± 0.02 NS NS < 0.05
Lung inflammation (0-4) 0.20 ± 0.17 3.0 ± 0.26 0.3 ± 0.21 1.2 ± 0.28 0.3 ± 0.33 < 0.05 < 0.05 < 0.05
Therapy with either drug, or both together, was begun 3 weeks following MCT, i.e., after PH had fully developed. ANOVA: p < 0.0001
* MCT + VIP vs. MCT; † MCT + Bosentan vs. MCT; ** MCT + VIP + bosentan vs. MCT
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mechanism and pathways, including: activation of: the
endothelin-endothelin receptor pathway [19]; the PDGF
(platelet-derived growth factor) pathway, a potent mito-
gen that stimulates proliferation and migration of pul-
monary vascular smooth muscle cells [23]; upregulation
of the serotonin transporter [24]; increased serine elas-
tase activity and proteinase-dependent deposition of
tenacin-C, which amplifies the response of smooth mus-
cle cells to growth factors [22]; the angiotensin system;
and Rho-kinase activity [25].
A variety of agents attenuate MCT pathology
By the same token, attenuation of the MCT-induced phe-
notype has been modulated by a variety of agents, includ-
ing: endothelin receptor antagonists, e.g. bosentan [19];
Imatinib, an inhibitor of PDGF; M249314, a serine elas-
tase inhibitor [22]; fasudil, an Rho kinase inhibitor [25];
drugs that increase cyclic GMP levels, such as promoters
of the L-arginine-endothelial nitric oxide synthase (eNOS)
pathway [26], and phosphodiesterase 5 inhibitors, such as
sildenafil [27]; as well as activators of cyclic AMP produc-
tion, such as prostacyclin analogs [28]. In addition, high-
lighting the important role of inflammation in
pathogenesis, specific inhibition of p38 MAP kinase,
selectively associated with inflammation, attenuated the
progression of PAH in MCT-treated rats [29].
Critique of the MCT model
1) All features of PAH in the MCT model were signifi-
cantly more pronounced than in the phenotype we
described in mice with deletion of the VIP gene [15]:
Thus, RV systolic pressure reached 61.4 ± 5.3 mm Hg
vs. 29.5 ± 1.1 mm Hg in VIP-/- mice (P< 0.001); RV/(LV
+Septum) was 0.56 ± 0.03 vs. 0.34 ± 0.01 (P< 0.001);
both vascular remodeling and the inflammatory
response were more severe, and survival was consider-
ably more limited in the MCT rat model (5-7 weeks) vs.
15 months in VIP-/- mice.
2) The MCT model has been criticized for not expres-
sing intimal proliferation, a feature of human PAH and,
overall, for being less of a therapeutic challenge than the
human disease [5,6].
3) Many drugs that have successfully reversed MCT
lesions in rats have failed to reverse the human PAH
lesions. However, reversal of MCT pathology is not
always guaranteed, as recently demonstrated for the
powerful rapamycin and statin combination [30].
A moderate response to bosentan
As predicted from earlier results by other investigators
[19], bosentan was moderately effective in reversing all
features of PAH in this model, being least effective in
correcting RVH. It also reduced mortality over the 45-
day observation period, from 100 to 29%.
A stronger response to VIP
The anti-PAH effectiveness of VIP is attributable to its
wide-ranging modulatory influence on multiple
pathways [20]. Analysis of gene expression in lungs of
VIP-/- mice revealed that deletion of the VIP gene leads
to under-expression of both BMP2 (bone morphogenetic
protein II) and BMPR2 [20], the latter being the princi-
pal gene mutation predisposing to Idiopathic and Famil-
ial PAH [31,32], along with over-expression of key pro-
proliferative and pro-inflammatory genes, and under-
expression of major anti-proliferative genes [20]. In
separate studies, we demonstrated that VIP selectively
down-regulates the expression of ET & ET receptors
[11]. With such a broad influence on critically important
genes controlling pulmonary vascular structure and
function, it is not surprising that VIP could have a
powerful, though incomplete, effect on the MCT-
induced pulmonary pathology. An earlier report
described beneficial effects for VIP in MCT-treated rab-
bits, following cardio-pulmonary bypass [33].
Prevention vs. reversal by VIP
Tested for its ability to reverse PAH after its develop-
ment, VIP treatment resulted in marked reduction in RV
systolic pressure, and medial area/luminal area, but only
slight reduction in RV hypertrophy. The failure of VIP to
induce more pronounced reversal of RVH compared to
RV hypertension can be explained by the relative ease of
reversing sustained pulmonary vasoconstriction com-
pared to attenuation of proliferative changes in pulmon-
ary vessels and RV. At the same time, mortality was
significantly reduced from 100 to 29% (P< 0.0001). By
comparison, early-treatment with VIP decreased all
pathologic features of PAH, including RV hypertrophy,
to a greater extent, and ensured full survival of rats
injected with an otherwise uniformly fatal dose of MCT.
Both in the prevention and reversal studies, VIP practi-
cally eliminated lung inflammation. Overall, VIP was
fairly effective in this model despite the greater severity
of the pathologic lesions, compared to VIP-/- model. The
reason VIP treatment was not as fully effective as in the
latter model was probably because of the complex under-
lying genotypic alterations [34].
The superiority of the VIP + bosentan combination
The most effective treatment regimen in these studies
was the combination of VIP and bosentan. All expres-
sions of PAH: RV systolic pressure, vascular remodeling,
RV hypertrophy, and Inflammation, were statistically
back to control values. In addition, combination therapy
totally eliminated mortality, just as with preventive VIP
treatment. The superiority of this combined therapy is
probably related to several factors: 1) the wide range of
pathways targeted by VIP [20]; 2) the complementary
synergistic anti-ET effect resulting from VIP-induced
down-regulation of both ET and ET receptor expression,
combined with ET receptor inhibition by bosentan [11];
and 3) the potent anti-inflammatory activity of VIP,
which assumes special significance in this model in view
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of the prominent inflammatory response elicited by
MCT [35]. Analysis of the influence of this combined
therapy on the expression of PAH-related genes and
pathways would provide helpful information in this
regard.
Gene expression alterations
As we reported elsewhere [34], genotypic analysis
showed 2 distinct sets of alterations in MCT-treated
rats: a) one, similar to that in VIP-/- mice, i.e., alterations
that tend to promote vascular remodeling and inflamma-
tion (e.g., up-regulation of myosin polypeptides, procol-
lagen, and some inflammatory genes); and b) another
set of alterations that suggest an effort to modulate the
PAH. (e.g., up-regulation of Vip and Nos3). Subsequent
treatment with VIP was partially successful in reversing
these genotypic abnormalities.
Conclusions
1) The findings demonstrate that VIP is effective, not only
against the PAH phenotype resulting from deletion of the
VIP gene, but also effective in preventing, and at least par-
tially reversing, the monocrotaline model of PAH.
2) The combination of VIP with bosentan has special
therapeutic advantages, because of the targeting of mul-
tiple pathogenetic pathways by both agents: VIP, with
its potent, pulmonary vascular-relaxant and anti-prolif-
erative effects, and bosentan with its synergism on the
endothelin-endothelin receptor system.
3) Overall, the results are particularly topical, because
of the present uncertainty about the therapeutic poten-
tial of VIP in human PAH: One clinical trial [13],
showed dramatic benefit, while a more recent trial, so
far published only as an abstract [18], reported negative
results. This report could help introduce a new line of
therapy with this peptide, alone or in combination with
other drugs, in this devastating disease.
4) While the conclusions of this study may not neces-
sarily apply to human PAH, they give added incentive to
the search for appropriate, especially advantageous drug
combinations against PAH. In particular, the findings
support the emerging hypothesis that, both experimental
models and clinical PAH are likely to benefit most from
appropriate combinations of anti-proliferative drugs.
Ideally, such combinations should be based on genotypic
information of the different forms of PAH, in accor-
dance with the concept of pharmacogenomics, which
has revolutionized therapy in oncology [36].
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